Arovella Therapeutics (ALA) investor relations material

Industry Context and Market Opportunity

• Cell therapy is rapidly evolving, dominating new oncology treatments and expanding into autoimmune diseases like lupus and Crohn's, with the CAR-T market projected to reach $15.2 billion by 2035.

• High-value deals for early-stage assets reflect strong sector interest and perceived value.

• Existing CAR-T therapies are patient-specific, costly, and time-intensive, with significant relapse rates and manufacturing challenges, highlighting the need for off-the-shelf solutions.

Platform and Technology Highlights

• The off-the-shelf CAR-iNKT platform uses healthy donor blood to manufacture multiple doses, reducing cost and improving patient access, with rapid dosing possible within one week.

• iNKT cells are allogeneic without gene editing, minimizing graft-versus-host disease risk and enabling broader application.

• The platform supports expansion into blood cancers, solid tumors, and autoimmune diseases, with a scalable, patented, and highly reproducible manufacturing process delivering consistent, potent drug product.

• CAR-INKT cells offer multiple tumor-killing mechanisms, can modulate the tumor microenvironment, and overcome limitations of autologous and allogeneic CAR-T and CAR-NK therapies.

Clinical Development and Pipeline

• Phase I trial for ALA-101 (CD19-targeting CAR-iNKT) in relapsed/refractory lymphomas and leukemias is set to begin dosing imminently, with preliminary data expected early 2027.

• The trial will enroll up to 46 patients, including those who failed or were ineligible for CAR T, and aims to establish safety, dosing, and B cell depletion efficacy.

• ALA-105, targeting Claudin 18.2 for solid tumors, is advancing with promising preclinical data and expected in vivo results in coming months, including applications in gastric and pancreatic cancers.